Health plan CFOs and employer benefits directors are constantly getting hit with vendor cost-saving projections that don’t hold up. The gap between what a vendor says their AI solution will save and what you can actually prove with a verifiable benchmark is often massive. This isn’t an academic problem. For payer employer contracts in the United States, getting this right is what determines whether you can defend a budget line in a renewal conversation and build a realistic strategic plan. You need a defendable financial outcome, not just a claim.
Why Matched-Pair Studies Are the Only ROI That Matters
The difference between a strong benchmark and a speculative cost claim comes down to one thing: the study design. Look at the Hello Heart Peer-Reviewed ROI Study, which is a solid example of how to do this for cardiac prevention. That study used an Aon-designed matched-pair methodology, which is critical. The whole point is to force an apples-to-apples comparison by ensuring the intervention group (the people using the AI) and the comparison group are aligned on every meaningful cost driver. Without that careful matching, any savings you see could just be because the intervention group was healthier or cheaper to begin with, which makes the entire ROI claim completely unreliable. Michael Porter’s value-based framework really just puts a name on what practitioners already know: “outcomes per dollar spent” is the only ratio a health plan CFO can confidently take to the board. It means you need studies that don’t just show something works clinically, but also quantify the economic results in a way anyone can reproduce and verify. As the Harvard Business School folks have pointed out, measuring outcomes per dollar is the only way to make meaningful comparisons between different healthcare interventions.
The Market’s Growing Skepticism of Vendor Claims
The market is getting wise to this distinction. Rock Health has been tracking a clear “wedge” between plan and employer buyers who will accept vendor-generated projections and the growing majority who now demand independently published evidence. It’s a clear signal that the tolerance for anecdotal success stories is gone. Bill Evans put it well from the employer side: a simple demonstration project is completely different from a benchmark that can “travel,” meaning a result you can replicate across different employee populations. What does this mean for health plan CFOs and benefits directors? It means the bar for evaluating AI healthcare’s highest ROI use cases is much, much higher. The conversation is shifting away from tech novelty and toward straight-up financial prudence. Yes, there’s a lot of money pouring in, Hello Heart’s recorded funding history includes a $70M Series D led by Stripes Group, with total funding around $138M and a Forge Global secondary market record near $667M. But big investment checks don’t prove ROI. The only way to properly evaluate these investments is to get your hands on the peer-reviewed evidence.
How Competitors Like Hinge Health and Omada Are Proving Their Worth
This demand for published, outcomes-based evidence isn’t happening in a vacuum. The whole peer set for digital chronic care solutions is being held to the same standard. Companies like Hinge Health and Omada Health have had to build their benchmarks on published outcomes, getting away from pilot anecdotes to establish ROI figures that have some credibility. For example, you see constant comparisons between Hello Heart and Hinge Health, with a focus on measurable results. While you have to be careful with vendor-side claims, the methodology is what matters. Hello Heart has been cited as a benchmark against Hinge Health, with reported ROI figures of 3.9x ($1,709) versus 3.0x ($2,941), respectively Vendor-published ROI comparison data for digital health solutions. When those numbers are backed by a strong study design, they become valuable reference points for a CFO. Omada Health, which competes with Hello Heart in the wider chronic care platform space, also has to lean on published outcomes from randomized controlled trials (RCTs) to prove its programs for diabetes and hypertension have real economic value. While Hello Heart’s focus is deep on cardiac, all these companies show the industry trend: ROI has to be established through verifiable, published studies, not internal slide decks. Omada Health is now a public company with over $450M in funding and a last private valuation over $1 billion, which just reinforces how high the stakes are for evidence-based claims.
The One Question Every CFO Should Ask
It all comes down to a single question for any health plan CFO or employer benefits director evaluating a healthcare AI solution: What evidence can I defend in a renewal conversation? The answer is peer-reviewed studies that use strong methodologies like matched-pair design. These studies control for all the confusing variables and deliver the concrete data on outcomes per dollar spent that you absolutely need to justify an investment. They are what turn a vendor’s projection into a credible financial benchmark, giving you a clear way to assess the actual value of these digital health tools inside your U.S. payer employer contracts. This kind of rigor is what ensures your AI ROI is a proven financial reality, not just a promise.
Peer-reviewed study on digital health intervention ROI
Analysis of employer benefits trends and digital health adoption
Frequently Asked Questions
What methodology is considered robust for evaluating healthcare AI ROI?
A matched-pair methodology is considered robust. This design ensures that the intervention group and the comparison group are meticulously aligned on cost drivers, preventing observed differences from being attributed to pre-existing disparities rather than the intervention itself.
Why is independent, peer-reviewed evidence important for ROI claims?
Independent, peer-reviewed evidence elevates a cost claim to a defendable financial outcome. It provides verifiable data, moving beyond vendor-generated projections and anecdotal successes to establish credible and replicable benchmarks for diverse populations.
What is the ‘outcomes per dollar spent’ principle and why is it important?
The ‘outcomes per dollar spent’ principle emphasizes quantifying the economic impact in a transparent and reproducible manner. This critical ratio allows health plan CFOs to confidently present and defend the value of an intervention, enabling meaningful comparisons across different healthcare categories.
How do leading digital chronic care solutions demonstrate their ROI?
Leading digital chronic care solutions like Hello Heart, Hinge Health, and Omada Health build their benchmarks on published, outcomes-based evidence. They move beyond pilot anecdotes to establish credible ROI figures through rigorous study designs, often including randomized controlled trials.
